Cover Image

Later-Line Treatment with Lorlatinib in <i>ALK</i>- and <i>ROS1</i>-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis

In clinical practice, patients with <i>anaplastic lymphoma kinase (ALK)</i>-rearrangement-positive non-small-cell lung cancer commonly receive sequential treatment with ALK tyrosine kinase inhibitors. The third-generation agent lorlatinib has been shown to inhibit a wide range of <i&g...

Full description

Saved in:
Bibliographic Details
Main Authors: Maximilian J. Hochmair (Author), Hannah Fabikan (Author), Oliver Illini (Author), Christoph Weinlinger (Author), Ulrike Setinek (Author), Dagmar Krenbek (Author), Helmut Prosch (Author), Markus Rauter (Author), Michael Schumacher (Author), Ewald Wöll (Author), Romana Wass (Author), Elmar Brehm (Author), Gudrun Absenger (Author), Tatjana Bundalo (Author), Peter Errhalt (Author), Matthias Urban (Author), Arschang Valipour (Author)
Format: Book
Published: MDPI AG, 2020-11-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items